Goldman Sachs analyst Chris Shibutani maintains Seres Therapeutics (NASDAQ:MCRB) with a Sell and lowers the price target from $4 to $1.25.
Goldman Sachs Maintains Sell on Seres Therapeutics, Lowers Price Target to $1.25
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.